FBIZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FBIZ is not a strong buy right now for a beginner long-term investor. The business fundamentals are healthy and Q1 2026 showed solid year-over-year growth, but the stock’s technical setup is neutral to slightly weak, there is no strong options or insider/smart-money confirmation, and there is no catalyst from recent news. For an impatient investor who wants to act now, this looks more like a hold than an immediate buy.
The current pre-market price is 56.72, which is just above the pivot at 56.399 and below the first resistance at 58.036. RSI_6 at 50.972 is neutral, so there is no clear momentum edge. The MACD histogram is -0.224 and still below zero, which suggests momentum remains mildly negative even though it is contracting. Moving averages are converging, pointing to a sideways setup rather than a strong uptrend. Near-term pattern data also leans mixed, with an estimated -2.22% move over the next week. Overall, the chart does not show a clean breakout signal.
["Q1 2026 revenue increased 7.65% YoY", "Q1 2026 net income increased 9.76% YoY", "Q1 2026 EPS increased 9.09% YoY", "Analysts remain constructive overall with Outperform ratings maintained", "Raymond James noted improving credit quality, strong fee income, and robust loan growth"]
["No recent news in the past week", "MACD remains below zero, indicating weak near-term momentum", "RSI is neutral, so the stock is not showing strong upside momentum", "No AI Stock Picker signal today", "No SwingMax signal recently", "No significant hedge fund or insider buying trends", "No recent congress trading data", "Analyst price target from Raymond James was lowered from $68 to $64"]
In Q1 2026, FBIZ posted healthy operating growth. Revenue rose to $41.10 million, up 7.65% year over year. Net income increased to $11.76 million, up 9.76% YoY, and EPS rose to $1.44, up 9.09% YoY. That is a solid quarter and shows the company is still growing profitably. For a long-term investor, the latest quarter is supportive of the business, though the stock price action has not yet fully confirmed that strength.
Analyst sentiment is moderately positive. Raymond James lowered its price target to $64 from $68 but kept an Outperform rating, citing solid quarterly results, improving credit quality, strong fee income, and robust loan growth. Keefe Bruyette raised its target slightly to $64 from $63 and also kept an Outperform rating. The Wall Street pros view is still constructive overall, but the slight target cut suggests expectations are not getting more aggressive.
